Signalife's 'Credit Card' Personal Event Monitor
Share:
GREENVILLE, S.C., Jan. 23 - Signalife, Inc. (AMEX:SGN), the revolutionary heart monitoring company, announced today that it has completed design and manufacturing specifications for fabrication of its state-of-the-art "personal" event monitor. The device, which is essentially the size of a "credit card," utilizes a micro-engineered version of the Company's patented "patient module" found in the flagship "Fidelity 100" product currently being distributed. The difference between the two devices is that the "Fidelity 100" utilizes the clinical standard of 12-leads for hospital, surgical and other standard medical environments. The "personal event monitor" - called the "Signalife Heart Card" ("SHC") - is held over the center of a patient's chest to detect cardiac status. A patient can carry the SHC in his wallet and pull it out at any time in order to monitor the cardiac signal emanating from his chest, for transmission and review by monitoring centers or physicians.
The Company has been developing the SHC for some time, and the fabrication specifications are of critical importance in view of the size and configuration of the device. Extensive testing was completed by the company in order to validate the precise specifications, and enable regulatory and manufacturing work to now be completed. It is anticipated that the device will be ready for full scale distribution in the third quarter of this year.
Budimir S. Drakulic, the Company's CTO, stated: "To have met this milestone in a timely manner is very exciting for the Company. I must congratulate our R&D team for hard work, vigorous testing and analysis that has gone into these fabrication models. When people in our society are able to access the use of our patented award winning "patient module" in over-the-counter settings (i.e., without prescription), the opportunity for cardiac disease evaluation and subsequent opportunity of prevention is obviously maximized."
The SHC must still pass regulatory approval, and subsequent testing as well as other scientific and manufacturing regulatory hurdles. The Company is confident that these will be timely accomplished and is looking forward to movement toward the marketplace.
About Signalife
Signalife, Inc. is a medical device company focused on the detection of cardiovascular disease through continuous ECG signal monitoring. The company's goal is to become the premier provider of cardiovascular disease monitoring products. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory environment. Signalife's revolutionary FDA-approved electrocardiograph (ECG) monitoring system called Fidelity 100 allows for the recording of a quality ECG signal from ambulatory cardiac patients. The Fidelity 100 will address a portion of the $400 billion cardiac disease market. Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. The company's website is available at: http://www.signalife.com/
CONTACT: Kevin Kading, Phone +1-212-918-4606, Cell +1-917-575-1920, kdng@prodigy.net
